Description of the medicine: Berodual (Berodual)
BERODUAL (Berodual) *.
Combined aerosol preparation containing b 2 -adrenomimetic phenoterol (berotek) and anticholinergic ipratropium bromide (atrovent).
The combination of the bronchodilating effect of drugs in Berodual that affect different pharmacological "targets" allows you to get a more pronounced bronchodilator effect with a lower dose of phenoterol and berotek.
The drug is especially indicated for the relief of acute attacks of suffocation and shortness of breath in bronchospastic syndrome. It can also be used for chronic obstructive bronchitis, emphysematous bronchitis and other bronchopulmonary diseases with the presence of bronchiolospasm.
Release form: in aerosol cans (with the dosing valve) with a capacity of 15 ml containing 300 doses of berodual. Each dose contains 0.5 mg of fenoterol hydrobromide (berotek) and 0.02 mg of ipratropium bromide (atrovent).
The usual dose for adults and children is 1 to 2 doses of an aerosol 3 times a day (if necessary, several times a day).
Precautions, possible complications and contraindications are the same as for the components that make up the drug (see Fenoterol, Ipratropium bromide).
A solution of Berodual for inhalation is also available with a manual atomizer or electro-nebulizer. A single dose is from 2 to 8 drops, which corresponds to 0.1 - 0.4 ml; 1 ml contains 0.25 mg of ipratropium bromide and 0.5 mg of phenoterol hydrobromide.